ArriVent BioPharma Overview
Valuation check: AVBP's P/E ratio is -7.73, below the sector sector average of 24.91.
Get informed when a big investor buys or sells
+ Follow-7.73
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
ArriVent BioPharma (AVBP) currently reports a P/E ratio of -7.73. That is below the sector sector average of 24.91. Use the charts on this page to explore ArriVent BioPharma's P/E ratio history and peer comparisons.
ArriVent BioPharma's P/E ratio of -7.73 is lower than the its sector sector average of 24.91. That is roughly 131.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates ArriVent BioPharma's market price to a fundamental measure such as earnings, sales, or book value. At -7.73, AVBP can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -7.73, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 24.91. From there, open related valuation or income-statement pages for ArriVent BioPharma, and consider following AVBP for alerts when major investors trade the stock.
